Submission systemSubmit
Advanced Search
Volume 4 Issue 2
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Frigid Zone Medicine  > 2024  >  4(2): 110-119
Liangliang Jiang, Qiushuang Qiao, Jing Wang. PLA2G2D and CHIT1: Potential biomarkers for immune infiltration and prognosis in cervical squamous cell carcinoma[J]. Frigid Zone Medicine, 2024, 4(2): 110-119. doi: 10.1515/fzm-2024-0012
Citation: Liangliang Jiang, Qiushuang Qiao, Jing Wang. PLA2G2D and CHIT1: Potential biomarkers for immune infiltration and prognosis in cervical squamous cell carcinoma[J]. Frigid Zone Medicine, 2024, 4(2): 110-119. doi: 10.1515/fzm-2024-0012
shu

PLA2G2D and CHIT1: Potential biomarkers for immune infiltration and prognosis in cervical squamous cell carcinoma

doi: 10.1515/fzm-2024-0012
  • 1.

    Department of Gynecological Tumor, Harbin Medical University Cancer Hospital, Harbin 150001, China

  • 2.

    Department of Pathology, Harbin Medical University Cancer Hospital, Harbin 150001, China

Funds:

Haiyan Foundation Youth Project JJQN2022-12

More Information
  • Corresponding author: Jing Wang, wangjing6507@hrbmu.edu.cn
  • Received Date: 2024-01-04
  • Accepted Date: 2024-02-06
    • Available Online: 2024-04-01
    Abstract
  •   Objective  The aim of this study was to identify biomarkers associated with immunity and prognosis in patients with cervical cancer.  Materials and methods  Data from patients with cervical squamous cell carcinoma (CESC) were retrieved from the UCSC Xena database and subjected to analysis. Gene sets representing 22 types of immunocytes were acquired, and immunocytes relevant to prognosis were identified. Weighted gene co-expression network analysis (WGCNA) was utilized to identify gene modules associated with prognosis-related immunocytes and to construct immune-related gene markers. Differentially expressed genes were then screened, and the association between immune score and biological function of immune-related gene markers was analyzed. Furthermore, tissue samples from cervical cancer patients in Northeast China were collected to validate the expression of two genes using real-time PCR and immunohistochemistry.  Results  This study identified 10 immunocytes significantly correlated with overall survival time in patients. Six gene modules were identified as significantly associated with prognosis-related immunocytes, with gene module 6 showing relevance to all prognosis-related immunocytes. Gene module 6 was related to all prognosis-related immunocytes. Moreover, two genes (including PLA2G2D and CHIT1) were found to be significantly associated with overall survival in cancer patients. Patients with CESC were classified into high and low immune score groups based on the median score of gene markers. Correlation analysis of the immune score and biological function was performed. Immunohistochemistry and real-time PCR results revealed high expression of CHIT1 and PLA2G2D in CESC tumor tissues.  Conclusion  PLA2G2D and CHIT1 show promise as biomarkers for evaluating immune infiltration and prognosis in patients with cervical cancer.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    Cohen P, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet, 2019; 393(10167): 169-182. doi: 10.1016/S0140-6736(18)32470-X
    [2]
    Mileshkin L, Moore K, Barnes E, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone: an international, openlabel, randomised, phase 3 trial. Lancet Oncol, 2023; 24(5): 468-482. doi: 10.1016/S1470-2045(23)00147-X
    [3]
    Xiao M, Xie L, Cao G, et al. CD4 T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. J Immunother Cancer, 2022; 10(5): e004022. doi: 10.1136/jitc-2021-004022
    [4]
    Oh D, Fong L. Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox. Immunity, 2021; 54(12): 2701-2711. doi: 10.1016/j.immuni.2021.11.015
    [5]
    Philip M, Schietinger A. CD8 T cell differentiation and dysfunction in cancer. Nat Rev Immunol, 2022; 22(4): 209-223. doi: 10.1038/s41577-021-00574-3
    [6]
    Sharonov G, Serebrovskaya E, Yuzhakova D, et al. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol, 2020; 20(5): 294-307. doi: 10.1038/s41577-019-0257-x
    [7]
    Huntington N, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer, 2020; 20(8): 437-454. doi: 10.1038/s41568-020-0272-z
    [8]
    Kurmyshkina O, Kovchur P, Schegoleva L, et al. T- and NK-cell populations with regulatory phenotype and markers of apoptosis in circulating lymphocytes of patients with CIN3 or microcarcinoma of the cervix: evidence for potential mechanisms of immune suppression. Infect Agent Cancer, 2017; 12: 56.
    [9]
    Zhang Y, Yu M, Jing Y, et al. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. Br J Cancer, 2021; 124(2): 414-424. doi: 10.1038/s41416-020-01123-w
    [10]
    Zhang L, Zhang H, Huang Y, et al. Expression of immune cell markers and tumor markers in patients with cervical cancer. Int J Gynecol Cancer, 2020; 30(7): 969-974. doi: 10.1136/ijgc-2020-001254
    [11]
    Sato H, Taketomi Y, Miki Y, et al. Secreted phospholipase PLA2G2D contributes to metabolic health by mobilizing ω3 polyunsaturated fatty acids in WAT. Cell Rep, 2020; 31(5): 107579. doi: 10.1016/j.celrep.2020.107579
    [12]
    Murakami M, Yamamoto K, Miki Y, et al. The roles of the secreted phospholipase A gene family in immunology. Adv Immunol, 2016; 132: 91-134. doi: 10.1016/bs.ai.2016.05.001
    [13]
    Miki Y, Yamamoto K, Taketomi Y, et al. Lymphoid tissue phospholipase A2 group ⅡD resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J Exp Med, 2013; 210(6): 1217-1234. doi: 10.1084/jem.20121887
    [14]
    Miki Y, Kidoguchi Y, Sato M, et al. Dual roles of group ⅡD phospholipase A2 in inflammation and cancer. J Biol Chem, 2016; 291(30): 15588-155601. doi: 10.1074/jbc.M116.734624
    [15]
    Liu H, Xu R, Gao C, et al. Metabolic molecule PLA2G2D is a potential prognostic biomarker correlating with immune cell infiltration and the expression of immune checkpoint genes in cervical squamous cell carcinoma. Front Oncol, 2021; 11: 755668. doi: 10.3389/fonc.2021.755668
    [16]
    Di Francesco A, Verrecchia E, Manna S, et al. The chitinases as biomarkers in immune-mediate diseases. Clin Chem Lab Med, 2022; 61(8): 1363-1381. doi: 10.1515/cclm-2022-0767
    [17]
    Chang D, Sharma L, Dela Cruz C. Chitotriosidase: a marker and modulator of lung disease. Eur Respir Rev, 2020; 29(156): 190143. doi: 10.1183/16000617.0143-2019
    [18]
    Lee C, Herzog E, Ahangari F, et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling. J Immunol. 2012; 189(5): 2635-2644. doi: 10.4049/jimmunol.1201115
    [19]
    Koralewski R, Dymek B, Mazur M, et al. Discovery of, a First-in-Class chitinase inhibitor as potential new therapeutics for idiopathic pulmonary fibrosis. J Med Chem, 2020; 63(24): 15527-15540. doi: 10.1021/acs.jmedchem.0c01179
    [20]
    Yu J, Zhang W, Ding D, et al. Bioinformatics analysis combined with experiments predicts PUDP as a potential prognostic biomarker for hepatocellular carcinoma through its interaction with tumor microenvironment. Front Oncol, 2022; 12: 830174. doi: 10.3389/fonc.2022.830174
    [21]
    Wang Q, Xu Y. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer. Front Pharmacol, 2022; 13: 1065701. doi: 10.3389/fphar.2022.1065701
    [22]
    Wen H, Chen H, Xie L, et al. Macrophage-related molecular subtypes in lung adenocarcinoma identify novel tumor microenvironment with prognostic and therapeutic implications. Front Genet, 2022; 13: 1012164. doi: 10.3389/fgene.2022.1012164
    [23]
    Zhou N, Kong D, Lin Q, et al. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment. Cancer Genet, 2023; 276-277: 17-29. doi: 10.1016/j.cancergen.2023.06.001
    [24]
    Garlanda C, Mantovani A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell, 2021; 39(8): 1023-1027. doi: 10.1016/j.ccell.2021.04.011
    [25]
    Verstockt B, Salas A, Sands B, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol, 2023; 20(7): 433-446. doi: 10.1038/s41575-023-00768-1
    [26]
    Lewis N, Sia C, Kirwin K, et al. Exosome surface display of IL12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared with recombinant IL12. Mol Cancer Ther, 2021; 20(3): 523-534. doi: 10.1158/1535-7163.MCT-20-0484
    [27]
    Jia Z, Ragoonanan D, Mahadeo K, et al. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front Immunol, 2022; 13: 952231. doi: 10.3389/fimmu.2022.952231
    [28]
    Goenka A, Khan F, Verma B, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond), 2023; 43(5): 525-561. doi: 10.1002/cac2.12416
    [29]
    Bule P, Aguiar S, Aires-Da-Silva F, et al. Chemokine-Directed tumor microenvironment modulation in cancer immunotherapy. Int J Mol Sci, 2021; 22(18): 9804. doi: 10.3390/ijms22189804
    [30]
    Ren X, Chen C, Luo Y, et al. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Mol Cancer, 2020; 19(1): 35. doi: 10.1186/s12943-020-01153-1
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(10)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (171) PDF downloads(13) Cited by()
    Proportional views
    Related

    Contact Us

    Editorial Office: Frigid Zone Medicine, Editorial Office of Frigid Zone Medicine, Heilongjiang Health Development Research Center, Zhongshan Road 112, Xiangfang District, Harbin, 150036, China

    Tel: 0451-87253028

    E-mail: editorialoffice@frigidzonemedicine.com

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    Links

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return